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Highlights 29 
1. We investigated RLS and LMR and their variants in PD and related disorders.  30 
2. A total of 49.2% of PD patients had any restlessness, including RLS and LMR.  31 
3. LMR variants and RLS variants are rare in PD and related disorders 32 
4. PD with restlessness was related to autonomic, sleep and depressive symptoms 33 
 34 
Abstract 35 
Objective: The objective of this study was to investigate the prevalence of restless leg 36 
syndrome (RLS), leg motor restlessness (LMR) and RLS/LMR variants and their 37 
relationship with clinical factors in patients with Parkinson’s disease (PD) and related 38 
disorders.  39 
Methods: Sixty-three PD patients, 17 multiple system atrophy (MSA) patients and 11 40 
progressive supranuclear palsy (PSP) patients were included in this study. Through 41 
face-to-face interviews, the patients were diagnosed with RLS/LMR, or with RLS/LMR 42 
variants in which the symptoms occur predominantly in body parts other than the legs. 43 
Results: The frequency of RLS, LMR, RLS variants and LMR variants was as follows: 44 
PD (12.7%, 11.1%, 0% and 1.6%); MSA (5.9%, 11.8%, 0% and 0%); and PSP (0%, 45 
9.1%, 0% and 0%). Restlessness without the urge to move was observed in 25.4% of the 46 
PD patients, 11.8% of the MSA patients and 0% of the PSP patients. The PD patients 47 
with restlessness exhibited higher Hoehn and Yahr stages and higher scores on the 48 
Scales for Outcomes in PD-Autonomic, PD sleep scale-2 and Beck Depression 49 
Inventory-II. The olfactory functioning, 123I-MIBG myocardial scintigraphy uptake 50 
and dopamine transporter single photon emission computed tomography findings did 51 
not differ between the PD patients with restlessness and those without. The severity of 52 
RLS was correlated with the autonomic symptoms.  53 
Conclusion: PD with restlessness was characterized by increased autonomic, sleep and 54 
depressive symptoms. Further studies including a large sample are warranted to 55 
characterize restlessness in PD and related disorders.   56 
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Introduction  57 
Patients with Parkinson’s disease (PD) show characteristic motor signs, such as 58 
bradykinesia, rigidity and rest tremors, due to the progressive degeneration of 59 
dopaminergic neurons in the substantia nigra. In addition, a wide range of nonmotor 60 
symptoms, such as sleep disturbances, cognitive impairment, olfactory disturbances and 61 
autonomic impairment, involve dopaminergic and nondopaminergic systems and are 62 
currently considered integral to the disease [1]. Sleep disturbances are common 63 
nonmotor symptoms that affect up to 90% of PD patients and are caused by various 64 
factors, including nocturnal motor and nonmotor symptoms, sleep-wake impairment 65 
related to the disease, comorbid restless legs syndrome (RLS) and rapid eye movement 66 
sleep behavior disorders.  67 
RLS is a sleep-related movement disorder characterized by the urge to move 68 
one’s legs and abnormal leg sensations while resting during the night that interferes with 69 
the sleep of sufferers [2]. Dopaminergic dysfunction has been suggested to play a role in 70 
RLS based on the clinical responses of patients with RLS to dopaminergic treatment, 71 
such as levodopa, ropinirole, rotigotine, pramipexole and cabergoline [3]. Dopaminergic 72 
medication mediated by D2 and D3 receptors is likely involved in the short-term 73 
improvement of RLS symptoms [4]. In patients with idiopathic RLS, especially severe 74 
cases, other body parts (face, trunk or arms) can be involved, but the legs should be 75 
more severely impaired than the other body parts. In contrast, RLS variants, such as 76 
restless face [5], arms [6] or abdomen [7], in which restlessness is restricted to or 77 
predominantly involves regions other than the legs with characteristics identical to those 78 
of RLS, has been reported. 79 
In patients with PD, the prevalence of RLS widely varies (0-50%) [8]. A recent 80 
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systematic meta-analysis showed that the RLS prevalence in PD patients is 81 
approximately 3 times higher than that in healthy controls [9]. A multicenter study 82 
showed that the prevalence of RLS among patients with multiple system atrophy (MSA) 83 
(28%) was higher than that in patients with PD (14%) and healthy controls (7%) [10]. 84 
Patients with progressive supranuclear palsy (PSP) showed severe sleep architecture 85 
impairment; however, RLS has not been well studied in PSP patients [11, 12].  86 
Similar to idiopathic RLS, RLS variants, such as restless lower back [13], 87 
perianal [14] and genital regions [15], have been described in PD patients. All of these 88 
patients responded well to adjunctive dopamine agonist therapy. Untreated patients with 89 
PD were 3-times more likely to have “leg motor restlessness” (LMR), which is 90 
characterized by the urge to move the legs but does not fulfill the 4 essential features of 91 
RLS [16], than healthy controls. Furthermore, we previously reported a patient with PD 92 
who presented with restless, uncomfortable sensations in the legs without the urge to 93 
move, which did not meet the criteria for RLS or LMR, as the initial manifestation of 94 
PD [17].  95 
We hypothesized that patients with PD and related disorders can show various 96 
types of restless and abnormal sensations in not only the legs but also other body parts, 97 
reflecting the endogenous brain dopamine deficiency. However, no studies have 98 
investigated the details of RLS-related symptoms and their clinical correlation in 99 
patients with PD and related disorders. The aim of this study was to evaluate the 100 
frequency of RLS, LMR and RLS/LMR variants and their relationship with clinical 101 
factors in patients with PD and related disorders, including PD, MSA and PSP.  102 
 103 
Methods 104 
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All study procedures involving human participants were performed in accordance with 105 
the ethical standards of the Institutional Research Committee and the 1964 Helsinki 106 
Declaration and its subsequent amendments or comparable ethical standards. All 107 
subjects enrolled in the study provided written informed consent. 108 
We performed a cross-sectional study investigating RLS and related symptoms 109 
in patients with PD and related disorders who visited the Department of Neurology, 110 
Dokkyo Medical University Hospital between June 2016 and April 2018. In total, 91 111 
patients with PD and related disorders (63 PD, 17 MSA and 11 PSP) who received a 112 
detailed clinical interview and assessment of restlessness were included in this study. 113 
The diagnosis of PD was made according to the Movement Disorders Society (MDS) 114 
diagnostic criteria for PD [18]. The diagnosis of MSA or PSP was made according to 115 
established criteria [19, 20]. Among the 17 patients with MSA, 6 patients had MSA with 116 
parkinsonism (MSA-P) symptoms, and 11 patients had MSA with predominant 117 
cerebellar ataxia (MSA-C). Patients with secondary parkinsonism due to medication, 118 
vascular lesions or trauma were excluded based on a brain imaging study and their 119 
clinical history. Patients with dementia, which was defined as Mini-Mental State 120 
Examination (MMSE) scores<20, were excluded from the study.  121 
 122 
Clinical assessment 123 
 124 
All participants completed questionnaires regarding their habits and sleep status. The 125 
PD sleep scale (PDSS)-2, which was designed to assess PD-related sleep problems and 126 
consists of 15 individual items, was used [21]. Daytime sleepiness was measured by the 127 
Japanese version of the Epworth sleepiness scale (ESS) [22]. The autonomic symptoms 128 
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were assessed using the Scales for Outcomes in PD-Autonomic (SCOPA-AUT) 129 
Japanese version [23]. The nonmotor symptoms were assessed by an interview using the 130 
Non-Motor Symptom Scale (NMSS) [24]. The depressive symptoms were evaluated 131 
with the Beck Depression Inventory (BDI)-II [25]. 132 
 RLS was assessed based on the criteria published by the International RLS 133 
Study Group (IRLSSG) [2]. The patients were diagnosed with RLS if the following four 134 
essential features occurred during the prior year after excluding other RLS mimics: 1) 135 
an urge to move the legs that is usually accompanied or caused by uncomfortable and 136 
unpleasant sensations in the legs; 2) the urge to move the legs and any accompanying 137 
unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying 138 
down or sitting; 3) the urge to move the legs and any accompanying unpleasant 139 
sensations are partially or totally relieved by movement, such as walking or stretching, 140 
at least as long as the activity continues; and 4) the urge to move the legs and any 141 
accompanying unpleasant sensations are partially or totally relieved by movement, such 142 
as walking or stretching, at least as long as the activity continues. The severity of 143 
restlessness was assessed with the IRLSSG rating scale (IRLS) [26]. 144 
The patients were diagnosed with LMR if they had the urge to move the legs 145 
during the prior year but did not fulfill the four essential features of RLS [16]. The 146 
patients were diagnosed with RLS/LMR variants if the abnormal sensations and 147 
restlessness predominantly or solely occurred in body parts other than the legs and their 148 
symptoms satisfied the four aforementioned criteria for RLS or LMR when applied in a 149 
modified manner to the involved body parts. Conditions that can mimic RLS or LMR, 150 
such as positional discomfort, muscle cramps, venous stasis, vascular claudication and 151 
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peripheral neuropathy, were excluded, and the diagnosis of RLS or LMR was confirmed 152 
[27]. Figure 1 shows the diagnostic flowcharts for RLS, RLS variants, LMR and LMR 153 
variants. TM performed detailed clinical interviews and assessments to diagnose the 154 
patients with RLS, RLS variants, LMR or LMR variants. If a patient had no urge to 155 
move based on the clinical interview but scored ≥1 point (1 or more days per week) on 156 
PDSS-2 subitem 4 (nocturnal restlessness), the patient was defined as having 157 
restlessness without the urge to move. 158 
The disease severity was rated based on the Hoehn and Yahr (HY) stage. 159 
Cognitive functioning was assessed with the MMSE. The levodopa equivalent dose 160 
(LED) was calculated according to previously described methods [28]. Parkinsonism 161 
was assessed with the Japanese version of the Movement Disorder Society-Sponsored 162 
Revision of the Unified Parkinson’s Disease Rating Scale part III [29]. In the patients 163 
with PD, the motor complications were assessed with the Japanese version of the 164 
MDS-UPDRS part IV. The clinical characteristics of the PD patients with restlessness 165 
(positive for RLS, LMR, RLS variants, LMR variants or restlessness without the urge to 166 
move) were compared with those of the PD patients without restlessness by DAT 167 
SPECT, MIBG cardiac scintigraphy and olfactory testing as described below.  168 
 169 
Cardiac 123I-metaiodobenzylguanidine scintigraphy 170 
 171 
Chest SPECT and planar images were obtained using a gamma camera 15 minutes 172 
(early phase) and 4 hours (delayed phase) after an injection of 111 MBq 123I-MIBG 173 
(FujifilmRI Pharma Co., Tokyo, Japan) [30]. Then, the heart-to-mediastinum (H/M) 174 
ratio was calculated by dividing the count density of the left ventricular region of 175 
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interest (ROI) by that of the mediastinal ROI. We used delayed MIBG imaging in this 176 
study.  177 
 178 
DAT SPECT 179 
 180 
123
I FP-CIT-SPECT imaging was performed 3 hours after an injection of 167 MBq (4.5 181 
mCi) [31]. The specific binding ratio (SBR) in the striatum was semiquantitatively 182 
determined and analyzed using QSPECT DAT quantification program (Molecular 183 
Imaging Labo Inc., Osaka, Japan). In this study, we used the averaged SBR values in the 184 
left and right striatum. 185 
 186 
Olfactory functioning 187 
 188 
A card-type odor identification test (Open Essence (OE), Wako, Japan) was used [32]. 189 
The usefulness of the OE test in PD-related disorders has been confirmed [33]. The OE 190 
test includes the following 12 different odors that are familiar to the Japanese 191 
population: India ink, wood, perfume, menthol, Japanese orange, curry, gas for 192 
household use, rose, Hinoki cypress, sweaty socks, condensed milk, and roasted garlic. 193 
During the test, when a subject opens the twice-folded card, a microcapsule breaks, and 194 
the odor is released. The subjects were asked to choose one of the following 6 possible 195 
answers: correct odor, odor closest to the correct odor, odor close to the correct odor, 196 
odor very different from the correct odor, detectable but unrecognizable odor, and no 197 
odor detected.  198 
 199 
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Statistical analysis 200 
 201 
Chi-square and Fisher’s exact tests were used to compare the categorical variables 202 
between the groups. Mann-Whitney U test and Student’s t-tests were used as 203 
appropriate to compare the continuous variables between the two groups. The 204 
correlation between IRLS and the other clinical parameters was analyzed with 205 
Spearman’s rank correlation coefficients. The differences in the continuous variables 206 
among the PD, MSA and PSP groups were assessed using the Kruskal–Wallis test, 207 
followed by Dunn’s post hoc test, or one-way analysis of variance, followed by 208 
Bonferroni’s post hoc test, as appropriate. A logistic regression analysis using a 209 
likelihood ratio forward selection model was performed to determine the contributing 210 
factors for restlessness in PD patients, adjusting for other clinical factors such as age, 211 
sex, disease duration, HY stage, LED, SCOPA-AUT, PDSS-2, and BDI-II. Two-tailed 212 
p-values<0.05 were considered statistically significant. IBM SPSS software V.25.0 213 
(IBM SPSS, Tokyo, Japan) and GraphPad Prism for Windows (V.7.0a; GraphPad 214 
Software, San Diego, California, USA) were used for the statistical analyses.  215 
 216 
Results 217 
 218 
Table 1 shows the clinical characteristics of the patients with PD, MSA and PSP. The 219 
PSP patients had higher HY stages than the PD and MSA patients. A total of 41.3% of 220 
PD patients, 82.4% of MSA patients and 36.4% of PSP patients were untreated. The 221 
MSA patients had lower LED, lower scores on PDSS-2 and higher scores of 222 
SCOPA-AUT than the PD patients. The PD patients exhibited higher scores on NMSS 223 
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than the MSA and PSP patients. The frequency of RLS, LMR and LMR variants was as 224 
follows: PD (12.7%, 11.1% and 1.6%); MSA (5.9%, 11.8%, and 0%); and PSP (0%, 225 
9.1% and 0%) (Table 2A). One MSA patient with RLS was MSA-P, and 2 MSA patients 226 
with LMR were MSA-P and MSA-C. None of the patients reported RLS variants. 227 
Restlessness without the urge to move, as assessed by PDSS-2 subitem 4, was observed 228 
in 25.4% of the PD patients and 11.8% of the MSA patients but was not observed in the 229 
PSP patients. Among the untreated groups, RLS, LMR and restlessness without the urge 230 
to move were observed in 11.5%, 7.7% and 23.1% of the PD patients and 7.1%, 14.3% 231 
and 7.1% of the MSA patients, respectively, while none of the PSP patients showed any 232 
restlessness. None of the untreated patients reported RLS variants or LMR variants 233 
(Table 2B). In Table 2, statistical comparisons among the groups were not performed 234 
due to the small number of MSA and PSP patients.  235 
 Among the 8 PD patients with RLS, 4 (50.0%) patients had bilateral symptoms, 236 
and 4 (50.0%) patients had unilateral symptoms. Two PD patients with RLS (20.0%) 237 
had RLS symptoms on the affected side. One MSA patient with RLS had bilateral 238 
symptoms. Among the 7 PD patients with LMR, all (100%) patients had bilateral 239 
symptoms. Two MSA patients with LMR had bilateral symptoms, and 1 PSP patient 240 
with LMR had bilateral symptoms. One PD patient with LMR variants had unilateral 241 
symptoms on the affected side.  242 
 Table 3 shows the differences in the characteristics between the PD patients 243 
with restlessness (positive for RLS, LMR, RLS variants, LMR variants or restlessness 244 
without the urge to move) and those without restlessness. The PD patients with 245 
restlessness (49.2%) had higher HY stages and higher scores on SCOPA-AUT, PDSS-2 246 
and BDI-II than the PD patients without restlessness. PD patients with restlessness had 247 
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a higher rate of dopamine agonist use and tended to have higher LED. The OE scores, 248 
averaged SBR values of the striatum on DAT SPECT and uptake of MIBG cardiac 249 
scintigraphy did not differ between the PD patients with and without restlessness. 250 
Regarding SCOPA-AUT subitems, there was no significant difference between PD 251 
patients with restlessness and those without restlessness, except for gastrointestinal 252 
function, which was higher in PD patients with restlessness (4.6±3.7 vs. 2.3±2.2, 253 
p<0.05). There were no gender differences in the frequency of RLS, LMR, RLS variants 254 
and LMR variants among PD patients (Supplementary Table 1). A logistic regression 255 
analysis showed that PDSS-2 (p<0.001; odds ratio, 1.292; 95%CI, 1.110-1.504) was the 256 
sole predictor for restlessness in PD patients, after adjusting for other clinical factors. 257 
Then, we assessed the correlations between the severity of restlessness and the 258 
clinical parameters using IRLS among the PD patients with restlessness (n=32). The 259 
IRLS scores positively correlated with SCOPA-AUT (r=0.48, p<0.05).  260 
 261 
Discussion 262 
 263 
This cross-sectional study was the first to perform detailed assessments of restlessness 264 
related disorders, such as RLS, RLS variants, LMR and LMR variants, among patients 265 
with PD-related disorders. The frequency of RLS and LMR was 12.7% and 11.1% 266 
among the PD patients, 5.9% and 11.8% among the MSA patients and 0% and 9.1% 267 
among the PSP patients, respectively. Although no statistical comparison was made 268 
among the PD, MSA and PSP groups, the frequency of RLS and LMR in the untreated 269 
patients with PD (11.5%, 7.7%) and MSA (7.1%, 14.3%) was likely higher than that in 270 
the patients with PSP (0%, 0%), suggesting that restlessness is related to the disease and 271 
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is not an effect of the dopaminergic treatment. Gjerstad et al [16] showed that the LMR 272 
prevalence in untreated PD patients was higher than that in age-matched healthy 273 
controls, but PSP and MSA patients were not included in their study. In our study, LMR 274 
variants, which have never been previously studied, were observed in 1.6% of the PD 275 
patients but not in the MSA and PSP patients. RLS variants, such as restless lower back 276 
[13] and perianal region [14], have been reported in patients with PD; however, we did 277 
not find RLS variants in this study in any group. Even though the PSP patients exhibited 278 
greater disease severity than the PD and MSA patients, the PSP patients did not report 279 
any restlessness (RLS, LMR or LMR variants). The unawareness of restlessness, which 280 
could possibly be related to the frontal lobe dysfunction in PSP, could play a role.  281 
Compared with the study by Zhu et al [34], in our study in PD patients, 282 
unilateral RLS symptoms were less frequent (50%) and only 1 PD patient had RLS 283 
symptoms on the affected side. Our PD patients with LMR all had bilateral symptoms, 284 
while the study by Zhu et al showed the majority of patients had unilateral LMR 285 
symptoms (94.4%) on the affected side (94.1%). Nomura et al [35] found that 35% of 286 
PD patients with RLS showed asymmetrical distribution of RLS symptoms, but there 287 
was no correlation between the predominantly affected side of PD and RLS symptoms. 288 
Bhalsing et al [11] found that all patients with PD and RLS had bilateral symptoms, 289 
despite the PD motor symptoms being asymmetric. A longitudinal study that included 290 
109 drug-naïve PD patients showed RLS prevalence increased from 4.6% at baseline 291 
evaluation to 6.5% after 2 years and to 16.3% after 4 years, suggesting disease 292 
progression along with increased dopaminergic medication had a role [36]. Although 293 
there has been no prospective study on LMR in PD patients, LMR was more common 294 
even in untreated PD patients than in healthy controls [16], which suggests that LMR 295 
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could represent PD-related sensorimotor symptoms. In our study, PD patients with 296 
restlessness tended to show longer PD duration, increased HY severity and LED, 297 
suggesting that RLS/LMR are PD-related symptoms. However, the reason for the 298 
difference in the rate of unilateral/bilateral RLS/LMR between our study and the study 299 
by Zhu et al [34] is unclear, but may be due to differences in the study population. 300 
In a previous study, PD patients with RBD showed reduced MIBG uptake 301 
compared with PD patients without RBD [37]. However, the difference in cardiac 302 
MIBG uptake between PD with and without restlessness has not been assessed 303 
previously. In patients with RLS, the SCOPA-AUT cardiovascular dysfunction domain 304 
was significantly impaired compared with control subjects [38], but in our study neither 305 
SCOPA-AUT cardiovascular dysfunction domain nor cardiac MIBG uptake were 306 
different between PD patients with and without restlessness, suggesting that cardiac 307 
autonomic impairment and restlessness are unlikely to be linked in PD patients. 308 
We found that PD patients with restlessness exhibited severe disease severity 309 
and increased autonomic, sleep and depressive symptoms compared with those without 310 
restlessness. Piao et al [39] reported that compared with PD patients without RLS, PD 311 
patients with RLS showed a significantly longer duration, higher disease severity and 312 
higher scores for motor symptoms, depression, anxiety, sleep disorders, fatigue and 313 
apathy, and increased transferrin and decreased iron, ferritin, dopamine and 314 
5-hydroxytryptamine contents in the cerebrospinal fluid. In their study, the 315 
SCOPA-AUT scores tended to be higher in PD patients with RLS compared with PD 316 
patients without RLS. The depression rate was higher in PD patients with RLS and 317 
LMR compared with those without restlessness [16]. These observations suggest that 318 
PD with RLS may be characterized by impaired neurotransmitter systems, such as 319 
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dopamine and serotonin, and iron in the brain. In contrast, Moccia et al [36] found a 320 
tendency toward the perseveration of dopamine transporter availability in the affected 321 
caudate and putamen in PD patients with RLS compared to those without restlessness. 322 
Dragan et al [40] also proposed the interesting hypothesis that RLS may delay the onset 323 
of PD based on observations that the onset age of parkinsonism was older in the 324 
RLS+PD (RLS preceding PD) group than that in the control PD group (without RLS). 325 
In this study, we did not find differences in SBR of the striatum on DAT SPECT 326 
between PD patients with and without restlessness. The IRLS score and DAT SPECT 327 
findings were not significantly correlated in the PD patients with restlessness. 328 
In our study, PD patients with restlessness had a higher rate of dopamine 329 
agonist use and tended to have higher LED than those without restlessness. It is possible 330 
that chronic dopaminergic treatment unmasked subtle or subclinical RLS in some PD 331 
patients. On the other hand, increased dopaminergic medication use in PD patients with 332 
restlessness could reflect progressed disease severity as rated by HY stage compared 333 
with PD patients without restlessness.  334 
RLS has been reported in 4.7-28% of MSA patients [41]. In MSA patients, 335 
RLS was not related to disease severity, LED or excessive daytime sleepiness [10, 42], 336 
but the prevalence of RLS tended to be more frequent in MSA-P patients than MSA-C 337 
patients [41]. In our study, among the MSA patients, one patient with RLS was MSA-P 338 
(1/1, 100%), and 1 of 2 patients with LMR was MSA-P (1/2, 50%).  339 
In our study, none of the PSP patients reported RLS, while the RLS prevalence 340 
was 12.7% and 5.9% among the PD and MSA patients, respectively. Similarly, Bhalsing 341 
et al [11] found that the prevalence of RLS in PSP patients (3.7%) and MSA patients 342 
(4.7%) was lower than that in patients with PD (11.9%). In contrast, in a study 343 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Page 15 
 
conducted by Gama et al [12] evaluating sleep disorders among patients with 344 
PD-related disorders, RLS was the most frequent in patients with PSP (57%), followed 345 
by PD (50.0%) and MSA (23.1%), and in PSP patients, the presence of RLS was 346 
associated with reduced sleep efficiency and sleep duration as assessed by the subitems 347 
on the Pittsburgh Sleep Quality Index. The wide difference in the RLS prevalence in 348 
PSP patients may account for the differences in the RLS diagnosis or evaluations 349 
employed among studies.  350 
Despite the widespread brainstem pathology in PSP patients, the ESS and 351 
PDSS-2 scores did not significantly differ among the PD, MSA and PSP patients. We 352 
excluded dementia, and the MMSE scores did not significantly differ among the groups 353 
in this study; however, this finding could possibly reflect an impairment in frontal lobe 354 
functioning in PSP patients. In PD patients, better cognition was reported to be a factor 355 
contributing to nighttime sleep problems [43]. A patient with PSP-parkinsonism who 356 
developed RLS after withdrawal from rotigotine has been reported [44]. In our study, no 357 
patient had PSP-parkinsonism, but none of the PSP patients had RLS or LMR. 358 
Suzuki et al [45] showed that PD patients with RLS or LMR had an increased 359 
rate of sleep-related symptoms. Additionally, in our study, the PD patients with 360 
restlessness, including RLS and LMR, exhibited higher scores on the SCOPA-AUT, 361 
PDSS-2 and BDI-II than those without restlessness, emphasizing the importance of 362 
assessing autonomic, sleep and depressive symptoms in patients complaining of 363 
restlessness. Unlike idiopathic RLS, nigrostriatal dopaminergic degeneration is evident 364 
in PD and related disorders, suggesting that RLS, LMR and RLS/LMR variants in PD 365 
and related disorders could be reflective of nocturnal sensorimotor symptoms and 366 
wearing off due to endogenous dopamine insufficiency. Therefore, adding a long acting 367 
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dopamine agonist treatment should be first considered. Although evidence is insufficient 368 
for PD with RLS, alpha 2 delta ligands (gabapentin, gabapentin enacarbil and 369 
pregabalin), which inhibit the release of excitatory neurotransmitters such as glutamate 370 
and attenuate postsynaptic excitability [46], should be considered when patients are 371 
already receiving high-dose dopaminergic treatment. Istradefylline was recently 372 
reported to successfully treat PD patients with RLS [47]. In addition, given that 373 
restlessness is related to severe disease severity and increased autonomic, sleep and 374 
depressive symptoms in PD patients, detecting restlessness could be a good opportunity 375 
to revisit the treatment of motor and other non-motor symptoms. 376 
The lack of statistical power due to the small number of MSA and PSP patients 377 
and the absence of healthy controls are the major limitations of the study. Additionally, 378 
the onset age of RLS or LMR was not assessed. In our study, we only used MMSE to 379 
rule out dementia, but given the various profiles of cognitive impairment in PD [48], 380 
additional cognitive assessment batteries are needed to evaluate cognitive function in 381 
patients with PD in a future study. A strength of our study was that one author, who is a 382 
trained neurologist (TM), carried out all the detailed assessments of restlessness through 383 
clinical interviews with all the participants in this study to differentiate RLS or LMR 384 
from their mimics.  385 
In conclusion, we evaluated restlessness, including RLS and LMR, in patients 386 
with PD, MSA or PSP. Restlessness in the PD patients was associated with the disease 387 
severity, autonomic symptoms, sleep disturbances and depressive symptoms. Further 388 
studies with larger sample sizes are warranted to characterize restlessness in PD and 389 
related disorders. 390 
 391 
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Figure legends 548 
Figure 1: Flow chart of RLS/RLS variants, LMR/LMR variants and restlessness 549 
without the urge to move in this study 550 
RLS=restless leg syndrome; LMR=leg motor restlessness 551 
 Table 1: Clinical characteristics of the patients with PD, MSA and PSP 
 
PD (n=63) MSA (n=17) PSP (n=11) p-value 
Age (years) 68.3±10.1 69.2±9.6 72.7±10.0 0.35 
Sex (M/F) 29/34 10/7 4/7 0.69 
BMI (kg/m
2
) 22.0±4.4 23.2±3.3 21.1±3.9 0.33 
Disease duration (years) 4.1±4.3 2.9±3.0 4.2±2.9 0.48 
MMSE 26.7±3.3 26.4±3.4 24.1±3.8 0.21 
Hoehn and Yahr stage 2.6±1.0 2.6±1.3 3.9±1.2*¶ 0.032 
MDS-UPDRS III 28.2±17.2 19.3±11.6 48.8±24.8 0.059 
MDS-UPDRS IV 1.3±3.3 - - - 
Untreated patients, n (%) 26 (41.3) 14 (82.4)* 4 (36.4)¶ 0.0076 
LED (mg/day) 244.2±326.3 47.1±117.9* 322.7±453.5 0.015 
Levodopa, n (%) 31 (49.2) 3 (17.6) 5 (45.5) 0.065 
Dopamine agonists, n (%) 22 (34.9) 1 (5.9)* 1 (9.1) 0.021 
SCOPA-AUT 10.7±7.7 13.9±12.5* 27.0±31.1 0.81 
PDSS-2 13.0±8.7 6.1±6.8* 10.0±10.8 0.029 
ESS 6.4±5.1 7.4±5.3 6.4±10.0 0.46 
Table 1
BDI-Ⅱ 13.5±10.3 13.4±12.8 11.0±17.5 0.47 
NMSS 31.0±37.6 15.1±33.1* 21.8±58.0* 0.0010 
 
The data are presented as the mean±standard deviation. Significant values (p<0.05) are shown in bold. 
*p<0.05 compared to the PD patient group; ¶p<0.05 compared to the MSA patient group. 
PD=Parkinson’s disease; MSA=multiple system atrophy; PSP=progressive supranuclear palsy; BMI=body mass index; 
MMSE=Mini-Mental State Examination; MDS-UPDRS=Movement Disorder Society revision of the Unified PD Rating Scale; 
LED=levodopa equivalent dose; SCOPA-AUT=Scales for Outcomes in PD-Autonomic; PDSS-2=PD Sleep Scale-2; ESS=Epworth 
Sleepiness Scale; BDI-II=Beck Depression Inventory-II; NMSS=Non-Motor Symptom Scale. 
 
Table 2: Prevalence of RLS, LMR, and RLS/LMR variants in PD and related 
disorders 
(A) Total patients 
 
PD (n=63) MSA (n=17) PSP (n=11) 
RLS, n (%) 8 (12.7) 1 (5.9) 0 (0) 
LMR, n (%) 7 (11.1) 2 (11.8) 1 (9.1) 
RLS variants, n (%)  0 (0) 0 (0) 0 (0) 
LMR variants, n (%)  1 (1.6) 0 (0) 0 (0) 
Restlessness without the 
urge to move, n (%) 
16 (25.4) 2 (11.8) 0 (0) 
 
(B) Untreated patients 
 
PD (n=26) MSA (n=14) PSP (n=6) 
RLS, n (%) 3 (11.5) 1 (7.1) 0 (0) 
LMR, n (%) 2 (7.7) 2 (14.3) 0 (0) 
RLS variants, n (%)  0 (0) 0 (0) 0 (0) 
LMR variants, n (%)  0 (0) 0 (0) 0 (0) 
Restlessness without the 
urge to move, n (%) 
6 (23.1) 1 (7.1) 0 (0) 
 
The data are presented as n (%). 
PD=Parkinson’s disease; MSA=multiple system atrophy; PSP=progressive supranuclear 
palsy; RLS=restless legs syndrome; LMR=leg motor restlessness 
 
Table 2
Table 3: Comparison of PD patients with and without restlessness 
 
PD without 
restlessness 
PD with 
restlessness* 
p-value 
Age (years) 68.5±10.5 68.1±9.9 0.89 
Sex (M/F) 13/18 16/16 0.52 
BMI 22.1±5.0 21.8±3.7 0.75 
Disease duration (years) 3.1±2.9 5.0±5.1 0.072 
MMSE 27.0±3.0 26.4±3.5 0.48 
HY stage 2.2±0.8 2.9±1.1 0.0095 
MDS-UPDRS III 25.4±14.6 30.9±19.2 0.21 
MDS-UPDRS IV 1.0±2.5 1.6±3.9 0.43 
Untreated patients, n (%) 15 (48.4) 11 (34.4) 0.26 
LED 167.9±271.5 328.1±360.7 0.067 
Levodopa, n (%) 14 (45.2) 17 (53.1) 0.53 
Dopamine agonist, n (%) 8 (25.8) 14 (43.8) 0.014 
SCOPA-AUT total 7.9±5.8 13.5±8.2 0.0046 
PDSS-2 8.0±5.3 17.7±8.8 <0.001 
ESS 5.1±3.9 7.6±5.9 0.053 
BDI-Ⅱ 10.0±7.1 16.6±11.8 0.013 
NMSS 28.1±29.1 33.8±44.4 0.56 
DAT SPECT  4.0±1.5 3.8±1.1 0.61 
MIBG cardiac 
scintigraphy 
2.2±1.2 1.8±0.8 0.13 
Open Essence 4.5±2.9 3.8±2.4 0.37 
IRLS  - 10.2±10.1 - 
 
The data are presented as the mean±standard deviation. Significant values (p<0.05) are 
shown in bold. 
*PD with restlessness group consists of RLS, LMR/LMR variants and restlessness 
without the urge to move. 
PD=Parkinson’s disease; BMI=body mass index; MMSE=Mini-Mental State 
Examination; MDS-UPDRS=Movement Disorder Society revision of the Unified PD 
Rating Scale; LED=levodopa equivalent dose; SCOPA-AUT=Scales for Outcomes in 
PD-Autonomic; PDSS-2=PD Sleep Scale-2; ESS=Epworth Sleepiness Scale; 
BDI-II=Beck Depression Inventory-II; NMSS=Non-Motor Symptom Scale; 
IRLS=International RLS Study Group rating scale. 
 
Table 3
Table 4: Correlations between the IRLS scores and clinical parameters in PD 
patients with restlessness 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
* p<0.05.  
IRLS=International Restless Legs Syndrome Study Group rating scale; BMI=body mass 
index; MMSE=Mini-Mental State Examination; MDS-UPDRS=Movement Disorder 
Society revision of the Unified PD Rating Scale; LED=levodopa equivalent dose; 
SCOPA-AUT=Scales for Outcomes in PD-Autonomic; PDSS-2=PD Sleep Scale-2; 
ESS=Epworth Sleepiness Scale; BDI-II=Beck Depression Inventory-II; 
NMSS=Non-Motor Symptom Scale. 
 
 
IRLS score 
 
correlation coefficient 
Age (years) -0.38 
BMI -0.14 
Disease duration (years) 0.04 
MMSE 0.13 
Hoehn and Yahr stage 0.09 
MDS-UPDRS Ⅲ 0.18 
MDS-UPDRS Ⅳ 0.13 
LED 0.08 
SCOPA-AUT 0.48 * 
PDSS-2 0.25 
ESS -0.14 
BDI-Ⅱ 0.16 
NMSS 0.03 
DAT SPECT  -0.29 
MIBG cardiac scintigraphy -0.32 
Open Essence -0.17 
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